Contraceptive-related cerebral venous thrombosis with profuse vaginal bleed
Introduction: Women on hormonal therapy for menorrhagia are at risk for cerebral venous thrombosis.
Case report: This scenario may become complicated when there is profuse vaginal bleed with the withdrawal of hormonal therapy. There are no reports describing the possible therapeutic approaches in this clinical situation.
Results: A 42-year-old female with a history of uterine fibroids and menorrhagia taking an estrogen-progesterone combination pill presented with seizure clusters. Neuro-imaging showed lateral sinus thrombosis and biparietal hemorrhagic infarcts. Withdrawal of the contraceptive pill was associated with profuse vaginal bleed, leading to hemodynamic instability and the need for multiple blood transfusions. As an emergent procedure to stop the vaginal bleeding, the patient was implanted with a levonorgestrel intrauterine system; with this, vaginal bleed stopped within 12 hours with hemodynamic stability. Subsequently, the patient was treated with unfractionated heparin followed by warfarin (target international normalized ratio: 2.5–3). She made a good neurological recovery.
Conclusion: This case illustrates that LNG-IUS can be an innovative choice for local hormonal therapy in a patient with OCP-related cerebral venous thrombosis and simultaneous vaginal bleeding.
Key WordsContraceptive pill menorrhagia cerebral venous thrombosis levonotgestrel intrauterine system
Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost 1996;76:477–478.PubMedGoogle Scholar
de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothombotic conditions. Br Med J 1998;316:589–592.Google Scholar
Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mnnucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793–1797.PubMedCrossRefGoogle Scholar
Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis: a review of 38 cases. Stroke 1985;16:199–213.PubMedGoogle Scholar
Preter MP, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis: follow-up of 77 patients. Stroke 1996;27:243–246.PubMedGoogle Scholar
Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldrop S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527–1534.PubMedCrossRefGoogle Scholar
Chopra JS, Banerjee AK. Primary intracranial sinovenous occlusions in youth and pregnancy. In: Vinken PJ, Bruyen GW, eds. Handbook of Clinical Neurology. Vol 10. Amsterdam: Elsevier Science Publishers BV, 1989, pp. 425–452.Google Scholar
Ikomi A, Perpa EF. Efficacy of the levonorgestrel intrauterine system in treating menorrhagia: actualities and ambiguities. J Fam Plann Reprod Health Care 2002;28:99–100.PubMedCrossRefGoogle Scholar
Cooper KG, Bain C, Parkin DE. Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomized trial. Lancet 1999;354:1859–1863.PubMedCrossRefGoogle Scholar
Vercellini P, Zaina B, Yaylayan L, et al. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol 1999;94:341–347.PubMedCrossRefGoogle Scholar
Pinto I, Chimeno P, Romo A, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment—a prospective, randomized, and controlled clinical trial. Radiology 2003;226:425–431.PubMedCrossRefGoogle Scholar
Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;4:CD000249.Google Scholar
Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56–72.PubMedCrossRefGoogle Scholar
Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355–363.PubMedCrossRefGoogle Scholar
Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhagia with a novel ‘frameless’ intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001;6:192–198.PubMedCrossRefGoogle Scholar
Macnab JL, Lowles IE. Levonorgestrel-releasing intrauterine system for menstrual dysfunction: patient satisfaction in the district general hospital setting. J Obstet Gynaecol 2002;22:402–405.PubMedCrossRefGoogle Scholar
Dolan LM, Mulholland M, Price J. The levonorgestrel intrauterine system: therapeutic application in family planning. J Fam Plann Reprod Health Care 2001;27:19–21.PubMedCrossRefGoogle Scholar
Fong YF, Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 1999;60:51–53.PubMedCrossRefGoogle Scholar
Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel “frameless” intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol 2002;102:74–79.PubMedCrossRefGoogle Scholar
Mercorio F, de Simone R, Di Spiezio Sardo A, Cerrota G, Bifulco G, Vanacore F, Nappi C. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003;67:277–280.PubMedCrossRefGoogle Scholar
Toivonen J Lukkainen T, Alloneri H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261–264.PubMedCrossRefGoogle Scholar